00:47 , Feb 23, 2019 |  BioCentury  |  Tools & Techniques

Modeling now for precision later

GNS Healthcare Inc. is building a platform that aims to make value-based payment models unnecessary by giving companies a way to know which patients will respond before they even launch the drug. While drug companies...
17:33 , Jan 11, 2019 |  BC Week In Review  |  Company News

bluebird's five-year pricing model for LentiGlobin could resonate with payers

A potential outcomes-based pricing scheme from bluebird bio Inc. (NASDAQ:BLUE) for its gene therapy could resonate with payers and proffer tentative solutions for navigating challenges around outcome tracking, patient portability and the Medicaid best price...
01:06 , Jan 9, 2019 |  BC Extra  |  Company News

bluebird's five-year pricing model for LentiGlobin could resonate with payers

A potential outcomes-based pricing scheme from bluebird bio Inc. (NASDAQ:BLUE) for its gene therapy could resonate with payers and proffer tentative solutions for navigating challenges around outcome tracking, patient portability and the Medicaid best price...
23:56 , Nov 5, 2018 |  BC Extra  |  Politics & Policy

Patient, consumer groups push back on biologics exclusivity

A group of 28 patient, consumer, labor, insurance and other organizations urged the Trump administration to reconsider the proposed 10-year brand-name biologic exclusivity provision in the U.S.-Mexico-Canada Agreement (USMCA). In a letter to U.S. Trade...
03:01 , Sep 1, 2018 |  BioCentury  |  Politics, Policy & Law

A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
00:51 , Jun 23, 2018 |  BioCentury  |  Strategy

Gawande’s Cheesecake Factory

Details about the healthcare organization Atul Gawande will run for Amazon.com Inc., Berkshire Hathaway Inc. and J. P. Morgan Chase & Co. are scarce -- basic facts, starting with its name, have not been disclosed....
13:01 , May 25, 2018 |  BioCentury  |  Product Development

Patients at the core

With excitement mounting for the seven hemophilia gene therapies in the clinic, the National Hemophilia Foundation wanted to avoid a scenario in which patients, physicians and payers had no good way to compare them. The...
16:33 , Apr 20, 2018 |  BC Week In Review  |  Company News

Highmark, AstraZeneca in outcomes-based Symbicort contract

Blue Cross Blue Shield's Highmark Inc. affiliate and AstraZeneca plc (LSE:AZN; NYSE:AZN) entered into an outcomes-based contract for Symbicort budesonide/formoterol to treat symptoms in chronic obstructive pulmonary disease (COPD) and asthma patients in Pennsylvania, West...
23:02 , Apr 17, 2018 |  BC Extra  |  Company News

Highmark, AstraZeneca in outcomes-based Symbicort contract

Blue Cross Blue Shield's Highmark Inc. affiliate and AstraZeneca plc (LSE:AZN; NYSE:AZN) entered into an outcomes-based contract for Symbicort budesonide/formoterol to treat symptoms in chronic obstructive pulmonary disease (COPD) and asthma patients in Pennsylvania, West...
00:48 , Feb 10, 2018 |  BioCentury  |  Politics, Policy & Law

Money in your pocket

Under intense pressure from President Donald Trump to take steps that visibly lower the cost of drugs, HHS Secretary Alex Azar is reaching for low-hanging fruit. The administration’s proposed budget, which will be released on...